|
|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING UROLOGY EXPERTS |
|
|
|
 |
|
|
The DORA Trial, Comparing Overall Survival in Patients Treat with Docetaxel vs. Docetaxel plus Radium-22
|
Michael Morris, MD
Michael Morris, Professor of Medicine and GU Medical Oncologist, Memorial Sloan Kettering Cancer Center joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to discuss the DORA trial. Michael Morris is the DORA trial principal investigator for this Prostate Cancer Clinical Trials Consortium (PCCTC) trial.
|
|
|
|
|
|
|
|
|
 |
|
|
Clinical Implications of the CARD Trial
|
Cora Sternberg MD, FACP
Cora Sternberg and Alicia Morgans discuss the recently presented results from the CARD trial at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019). The results of the CARD trial were initially presented at the 2019 ESMO meeting along with the simultaneous publication in the New England Journal of Medicine.
|
|
|
|
|
|
|
|
|
 |
|
|
Implementing Genetic Testing Into Clinical Practice
|
Mary-Ellen Taplin, MD
Mary-Ellen Taplin joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to speak about germline testing. They discuss what is required in implementing genetic testing into clinical practice and ways of disseminating the data to perform germline testing across the field of medical oncologists and urologists in the community.
|
|
|
|
|
|
|
|
|
 |
|
|
Integrating PARP inhibitors into the Standard of Care for Prostate Cancer
|
Joaquin Mateo, MD, PhD
At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) Joaquin Mateo joins Charles Ryan to discuss how PARP inhibitors are being integrated into the standard of care for prostate cancer, pivotal studies that are reporting and ongoing with PARP inhibitors, and important aspect of those studies that clinicians should integrate into his or her clinical daily life.
|
|
|
|
|
|
|
|
|
 |
|
|
Antibody-drug conjugates for metastatic urothelial carcinoma & 177Lu-PSMA-617 for Progressive mCRPC
|
Scott Tagawa, MD
Scott Tagawa joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) and discusses advances in bladder and prostate cancer. He highlights his recent work on antibody-drug conjugates (ADCs) in urothelial cancer and his presentation from ESMO on the initial results from TROPHY-U-01.
|
|
|
|
|
|
|
|
|
 |
|
|
The Journey of an Aspirational Leader
|
Lynn Seely, MD
President and CEO of Myovant Sciences, Lynn Seely joins Alicia Morgans and shares highlights of her career journey and of her keynote presentation during the Annual PCF Women in Science Forum at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019).
|
|
|
|
|
|
|
|
|
 |
|
|
Aiding Cancer Prevention and Treatment by Renaming the BRCA1, BRCA2, and BRCA3 Mutations
|
Colin Pritchard, MD, PhD
Colin Pritchard from the University of Washington joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to speak about his recent editorial that was published in Nature that advocates for a renaming of the genetic syndrome that we commonly call BRCA2 mutation or the "breast cancer gene".
|
|
|
|
|
|
|
|
|
|
